Treatment

Genetics for personalized stroke prevention and management 11:03
Genetics for personalized stroke prevention and management
Anita Arsovska • 1 Jun 2021
Using video analysis to evaluate nelotanserin as symptomatic treatment for RBD in dementia 2:56
Using video analysis to evaluate nelotanserin as symptomatic treatment for RBD in dementia
Ambra Stefani • 23 Jun 2021
Therapeutic targeting of the safety factor in myasthenic syndromes 2:44
Therapeutic targeting of the safety factor in myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Eptinezumab initiated during a migraine prolongs time to subsequent attacks 4:37
Eptinezumab initiated during a migraine prolongs time to subsequent attacks
Roger Cady • 15 Jun 2021
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials 2:41
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials
Roger Cady • 15 Jun 2021
How does eptinezumab differ from other migraine treatments? 2:27
How does eptinezumab differ from other migraine treatments?
Roger Cady • 15 Jun 2021
What does an MS diagnosis mean for patients today? 2:02
What does an MS diagnosis mean for patients today?
Giancarlo Comi • 21 Jun 2021
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack 4:47
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack
Roger Cady • 15 Jun 2021
Exciting developments in the neuromuscular field 1:52
Exciting developments in the neuromuscular field
Gabriele Siciliano • 15 Jun 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:55
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
Unanswered questions: cannabinoids for the treatment of epilepsy 2:36
Unanswered questions: cannabinoids for the treatment of epilepsy
Andreas Schulze-Bonhage • 11 Jun 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Apitegromab for the treatment of SMA 2:49
Apitegromab for the treatment of SMA
Gabriele Siciliano • 15 Jun 2021
Broadening the applications of CBD in epilepsy syndromes 2:15
Broadening the applications of CBD in epilepsy syndromes
Andreas Schulze-Bonhage • 11 Jun 2021
Next steps in MS treatment: optimizing what we have 3:36
Next steps in MS treatment: optimizing what we have
Giancarlo Comi • 21 Jun 2021
The content of VJNeurology is intended for healthcare professionals